UK markets close in 8 hours 22 minutes

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,065.00-5.00 (-0.47%)
As of 4:41PM BST. Market open.
Sign in to post a message.
  • R
    RV
    I bought these to complement my gene editing stocks- and this has taken off today.
  • C
    Christina
    A key challenge in unlocking gene editing (like CRISPR) potential is delivery. MaxCyte is a company that can cheaply, quickly, and reliably deliver gene editors into a lot of cells for ex vivo therapies. You get the upside of cell therapy market growth while diversifying risk across a dozen, potentially hundreds, of therapies.

    I talk more about Maxcyte in this article: https://healthandwealth.substack.com/p/maxcyte-electroporation
    How MaxCyte makes revenue from cell-therapy companies like CRISPR Therapeutics, Editas, and Caribou's R&D expenses
    How MaxCyte makes revenue from cell-therapy companies like CRISPR Therapeutics, Editas, and Caribou's R&D expenses
    healthandwealth.substack.com
  • C
    Cannuck #3
    @RV what do you think of Bio genomics (bngo) and Genprex (GNPX) thank you for your input
  • 8
    8989
    What is going on with MXCT? Keeps dropping since I bought it.
  • R
    RV
    What does crbu, beam, ntla , crsp, edit, allo, grph ,dtil ,sgmo sana all have in common?

    Answer: Maxcyte -mxct

    Extrapolated cells- the name in the game for CAR-T and CAR-NK therapy.
  • C
    Cannuck #3
    @RV are there any more you are following and are at really early stage?
  • C
    Cannuck #3
    @RV where do you find them. Is there a place or site where one can look?
  • R
    RV
    ct
    @buysidebio
    ·
    4m
    I think $MXCT is the next $RGEN. TMO should scoop them sooner than later
  • R
    RV
    MoatsLikeKodak@MoatsLikeKodakI think $MXCT is a really simple idea with limited downside and multi-bagger upside. PTs in a tight range from $19 - $22 probably make many think there's not much upside. I think it's an obvious asymmetric bet at any price at or below that range At ~100m shares outstanding, MC is ~$1.4b Biz Model is: * razor/blade * milestone payments * royalties It's clear a SOTP valuation is req'd and it's not the same SOTP as holding co's We have right now: $250m net cash platform worth $300m - $600m royalties for CTX001 valued at >$90m per 1% royalty (implies ~75% odds of approval)There's your downside. If everything goes to hell, CTX001 causes obvious and immediate cancer in patients, MXCT is worth ~$750m That's pretty sweet. What's the upside? Language goes from planning for CTX001 approval to implying it will be FDA approved, to approval (roughly in early 2023?) This chain of positive news increase value of the CTX001 royalty (as the prob of success increases), all other royalties (all gene editing is linked, so #$%$ ticks up), we are closer in time and most use discount rate of 11%, and the discount rate used to value MXCT declines I don't think people will appreciate this tweet but thinks of all these drivers in your DCF: * odds of probability-linked cash flow increases * time to receiving cash flows decreases * discount rate used to value cash flows decreases (11% -> ~6% since majority CFs are royalties) Again, assuming MXCT doesn't increase business at all, we are looking at valuation of: $180m revenue/SPL * 14 SPL partnerships = $2.5b $600m platform value $250m cash = $3.35b value Still need to discount SPL partnerships some in 2023 but it's clear how value accretes Approval of CTX001 increases the TAM of therapies that use ex vivo, will increase funding for gene editing (which increases potential partnerships). If each SPL signed is worth $85m today (moving towards $100m with CTX001 approval), you can see how value potential moves up All these catalysts still leave room for the next investor to earn a fair return relative to the assets they are purchasing. 6% return on royalties is a sweet deal. But wait, there's more... The biggest drawback cited by customers is that MXCT has no upstream or downstream offerings. It's clear MXCT is superior tech, but they have to pair it with other offerings MXCT is an obvious buyout candidate for $TMO or $LZAGY. It's straightforward synergistic move for either Maybe MXCT builds their own business but for ~$4b in 2023, TMO/LZAGY can own the full suite for gene editing The r/r is easy here: * there's protected downside * easily defined catalysts with reasonably estimated likelihood * high upside (200%+ in 2 years?)
  • R
    RV
    Got 590 @ $15.05 today.
  • R
    RV
    Finally going up.
  • R
    Rex
    See earnings date is 13th September
    Will be interesting
  • R
    RV
    Future vaccines for quicker delivery:

    https://medicalxpress.com/news/2021-03-vaccines-lungs-boost-immune-responses.html
    Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer: study
    by Sarah McDonnell, Massachusetts Institute of Technology
  • R
    RV
    Doing well today.
  • R
    RV
    This sure was a very good day for this stock.
  • s
    stocktargetadvisor
    $MXCT
    Initiates Coverage On William Blair Outperform
    Initiates Coverage On Stephens & Co. Overweight USD 19
    Initiates Coverage On BTIG Research Buy USD 22
    Initiates Coverage On Stifel Nicolaus Buy USD 18
    Initiates Coverage On Cowen Outperform
  • A
    Asian Tiger
    About to cross the rubicon with a US investor base who understand how big cell therapy can be.
  • D
    Danny
    This will be HUGE in a year or two. Trust me.
  • A
    Aaron
    Anyone here?